Protein Kinase C-theta Phosphorylation of Moesin in the Actin-binding Sequence*

Salvatore F. Pietromonaco, Peter C. Simons, Amnon AltmanDagger , and Laurence Elias§

From the Department of Internal Medicine and the Cancer Research and Treatment Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 and the Dagger  Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92121

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Moesin, a member of the ezrin-radixin-moesin (ERM) family of membrane/cytoskeletal linkage proteins, is known to be threonine-phosphorylated at Thr558 in activated platelets within its conserved putative actin-binding domain. The pathway leading to this phosphorylation step and its control have not been previously elucidated. We have detected and characterized reactions leading to moesin phosphorylation in human leukocyte extracts. In vitro phosphorylation of endogenous moesin, which was identified by peptide microsequencing, was dependent on phosphatidylglycerol (PG) or to a lesser extent, phosphatidylinositol (PI), but not phosphatidylserine (PS) and diacylglycerol (DAG). Analysis of charge shifts, phosphoamino acid analysis, and stoichiometry was consistent with a single phosphorylation site. By using mass spectroscopy and direct microsequencing of CNBr fragments of phospho-moesin, the phosphorylation site was identified as KYKT*LRQIR (where * indicates the phosphorylation site) (Thr558), which is conserved in the ERM family. Recombinant moesin demonstrated similar in vitro phospholipid-dependent phosphorylation compared with the endogenous protein. The phosphorylation site sequence of moesin displays a high degree of conservation with the pseudosubstrate sequences of the protein kinase C (PKC) family. We identified the kinase activity as PKC-theta on the basis of immunodepletion of the moesin kinase activity and copurification of PKC-theta with the enzymic activity. We further demonstrate that PKC-theta displays a preference for PG vesicles over PI or PS/DAG, with minimal activation by DAG, as well as specificity for moesin compared with myelin basic protein, histone H1, or other cellular proteins. Expression of a human His6-tagged PKC-theta in Jurkat cells and purification by Ni2+ chelate chromatography yield an active enzyme that phosphorylates moesin. PG vesicle binding experiments with expressed PKC-theta and moesin demonstrate that both bind to vesicles independently of one another. Thus, PKC-theta is identified as a major kinase within cells with specificity for moesin and with activation under non-classical PKC conditions. It appears likely that this activity corresponds to a specific intracellular pathway controlling the function of moesin as well as other ERM proteins.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Moesin is a member of the ERM1 family of actin cytoskeletal-membrane linkage proteins. Although closely related, there is evidence that these proteins have distinct functions, based upon their patterns of intracellular and tissue distribution. Moesin is named for its association with extracellular extensions (membrane-organizing-extension spike protein). ERM proteins have N-terminal membrane-binding domains and C-terminal actin-binding domains. Relatively little is known about their intracellular control, although phosphorylation of moesin Thr558 by an unidentified kinase in activated platelets has recently been described (1). This residue is within the previously identified actin-binding domain of ezrin, which is highly conserved in moesin (2).

This laboratory has been studying a distinctive protein phosphorylation reaction characterized by stimulation of more than 10-fold with the addition of appropriate phospholipid vesicles in the presence of Mn2+, in preference to Mg2+, but not requiring Ca2+ (3-5). Under these conditions phosphorylation was strikingly specific for two major endogenous substrates from human leukemic cell extracts, which were 47 and 73 kDa by SDS-PAGE. This activity was found to be most highly expressed in both normal and malignant hemopoietic cells and tissues of both human and murine origin. We noted the activation requirements of these reactions to contrast with those of classical PKC isozymes and therefore embarked upon the purification and identification of the components of this system from human leukocytes. Previously, we identified the 47-kDa substrate as the small calpain fragment of talin, a protein which has homology to ERM proteins and is involved in focal adhesions of cells to substratum (6). We here report the purification and identification of the 73-kDa substrate as moesin. We furthermore have identified the moesin kinase present in our cell extracts as protein kinase C-theta , a novel PKC isozyme, which is known to be highly expressed in hemopoietic lineage cells but is of unknown function. These results thus provide evidence for a novel pathway of control of ERM proteins by PKC-theta . The results also provide insights into the specificity of PKC-theta for moesin and the activation requirements for PKC-theta , which has not previously been shown to be activated by Mn2+ and PG.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

All electrophoresis materials were supplied by Bio-Rad, and all other chemicals, as well as the catalytic subunit of PKA, were supplied by Sigma unless otherwise noted. Protein kinase C (PKC), purified from rat brain, was obtained from Lipidex (Westfield, NJ) and is a mixture of isozymes. Isozyme-specific anti-PKC sera used for immunodepletion experiments were obtained from R & D Ab Diagnostics (Berkeley, CA). These antibodies, with the exception of anti-PKC-epsilon , are capable of immunoprecipitation. Anti-PKC-theta specific for the V3 region of PKC-theta was used as described previously (7); anti-PKC-theta (F-13) specific for the C-terminal residues 691-703, anti-PKC-alpha (C-20) specific for C-terminal residues 651-672, and anti-His6 probe (H-15) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies and reagents for ECL detection were obtained from Amersham.

In Vitro Phosphorylation-- Phosphorylation reactions were carried out as described previously (6), except that the phospholipid was sonicated in water for 30 min to produce a suspension of vesicles. After the reaction, proteins were precipitated by adding 1/10 volume of 0.15% deoxycholic acid, mixing, and then quickly adding 1/10 volume of 100% (w/v) trichloroacetic acid, mixing, and centrifuging in a microcentrifuge for 5 min. This method improves protein yield and results in a stable precipitate (8). The precipitate was rinsed once with 20 µl of water, dissolved in 10 µl of 1× Laemmli sample buffer at 56 °C for 10 min, and subjected to 10% SDS-PAGE as described (9). The gels were stained with Coomassie Blue and dried between cellophane sheets, and autoradiograms were made. Protein determinations were done as described (10).

Purification of the pp73-- Purification of the 73-kDa substrate was carried out as described previously, including ammonium sulfate fractionation and chromatography of proteins on CM-cellulose (6), which was based on earlier work (11). Fractions from a gradient elution of the CM-cellulose column were assayed for PG-stimulable phosphorylation of a 73-kDa substrate, and the peak fractions (about 0.1-0.15 M NaCl) were combined and concentrated using a PM-30 membrane (Amicon, Beverly, MA); 40 ml of pelleted acute myelogenous leukemia (AML) cells from a patient gave 4 ml of CM-cellulose fraction with 14 mg of protein. 400 µl of this was adsorbed to PG vesicles as in the assay (800 µl total), incubated at 30 °C for 5-15 min, put on ice for 5-15 min, and then spun in a microcentrifuge for 10 min. The supernatant was removed, and the PG vesicles including adsorbed proteins were suspended in 200 µl of 0.5% Nonidet P-40, 0.6% Ampholines, pH 6-7 (Serva; Crescent Chemicals, Hauppauge, NY), 0.4% Ampholines, pH 3.5-10, 8% sucrose. This was divided between two isoelectric focusing tubes 0.15 cm inner diameter by 18 cm, containing a 0-40% sucrose gradient plus the Ampholines listed above, as described (12). 100 V was applied for 18 h and then 0.25-ml fractions were collected through a 26-gauge needle and analyzed by SDS-PAGE. The three fractions containing pp73 (determined by a 32P-radiolabeled tracer and SDS-PAGE) were co-precipitated with deoxycholate plus trichloroacetic acid as described above and rinsed on ice with 50 µl of cold acetone. The precipitates were submitted to the W. M. Keck Biotechnology Resource Laboratory, Yale University (New Haven, CT) for trypsin digestion, HPLC separation of the resulting peptides, and Edman sequencing of two of the peptides. One peptide gave a major and a minor sequence. To identify the phosphorylation site, 32P-labeled moesin was digested with CNBr, and the peptides were purified by reverse phase HPLC on a Vydac C18 column using a gradient of acetonitrile in 0.1% trifluoroacetic acid. The radioactive peak was analyzed by mass spectroscopy using matrix-assisted laser desorption (performed at the Yale University facility). This system is capable of 1-Da accuracy at 3500 Da. Manual amino acid sequencing of the 32P-labeled moesin peptides was performed as described (13).

A further partial purification of moesin, starting at the CM-cellulose pool, resulted in separation of moesin, moesin kinase, and phosphatase activity. The CM-cellulose pool was equilibrated in 0.02 M Tris, pH 7.5, applied to a column of DEAE 8HR (Millipore, Bedford, MA), and eluted with a linear gradient to 0.5 M NaCl. moesin eluted at about 0.25 M NaCl, just before the endogenous kinase activity.

Bacterial Expression of Human Moesin-- cDNA to human moesin was generously given by H. Furthmayr (Stanford University) in plasmid form. Double-stranded cDNA was generated by the polymerase chain reaction, making the two BglI fragments of moesin, using the following two primer pairs: 5'-CATGCCCAAAACGATCAGTGT plus 5'-CAAGGCCTCCTTGGCCTCT and 5'-TTACATAGACTCAAATTCGTCAAT plus 5'-AGAGGCCAAGGAGGCCTTG. The products were cut with BglI (14) and ligated, and after agarose gel electrophoresis, full-length moesin cDNA was obtained using Geneclean (Bio 101, La Jolla). Primers were synthesized to allow insertion into the NheI to KpnI site of the bacterial expression vector pRSETA (Invitrogen, San Diego): 5'-CCGGCTAGCATGCCCAAAACGATCAGTGT plus 5'-GCGGGTACCTTACATAGACTCAAATTCGTCAAT. The resulting DNA was ligated into the vector and used for transformation of Escherichia coli BL21(DE3) containing pLys S for expression of protein (15). This sequence codes for moesin preceded by the protein "tag" MRGSHHHHHHGMAS; the six-histidine (His6) tag binds tightly to a nickel (Ni2+) chelate column (see below).

Protein expression was adequate in E. coli grown in L broth at 37 °C in the absence of inducer. 50 ml of L broth supplemented with ampicillin and chloramphenicol were inoculated with a fresh colony, grown for 8 hours, and centrifuged at 5,000 × g for 10 min. The cell pellet was resuspended in water to a total volume of 4 ml and then quick frozen. The thawed suspension was sonicated with 40 bursts from a microtip at 30% duty, using a Bronson sonifier set at output 2. Cellular debris was removed by centrifugation at 12,000 × g for 20 min, and the 3.2 ml of supernatant was combined with 3.2 ml of "bind" buffer and applied to a 2-ml Ni2+ chelate affinity column (Invitrogen). The column was rinsed according to the supplier's instructions, and the recombinant moesin was eluted with an imidazole gradient from 0 to 400 mM imidazole. Fractions were analyzed by SDS-PAGE, and those containing moesin were combined and equilibrated in 10 mM BisTris, pH 6.5, 0.1 mM EDTA, 1 mM 2-mercaptoethanol by passage through a P6DG column (Bio-Rad). Residual phosphatases were removed by passage through a 1-ml CM-cellulose column with a 0-0.3 M NaCl gradient over 10 ml. Fractions of 1 ml were again analyzed by SDS-PAGE, and fractions 5-7 were combined, and glycerol was added to 7%, and the preparation was frozen. Recombinant His6-moesin was judged to be >90% pure by SDS-PAGE and Coomassie Brilliant Blue staining.

Immunodepletion of Moesin Kinase Activity-- Isozyme-specific PKC rabbit antibodies were purified from crude antisera by performing a 40% ammonium sulfate precipitation. This step effectively removed phosphatase activity present in serum. The precipitated IgG fraction was dialyzed into TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl), and the total protein was estimated by SDS-PAGE using different amounts of molecular weight standards. An aliquot of the CM-cellulose-purified moesin kinase was incubated with 1 µg each of the isozyme-specific and non-immune IgG in TBS at 4 °C for 60 min, followed by protein A/G-agarose (Santa Cruz Biotechnology, Santa Cruz) for an additional 30 min. The beads were collected by centrifugation, and the supernatant was used in the moesin kinase assay described above.

Purification of Moesin-specific Protein Kinase Activity from AML Cells-- Each step in the purification of protein kinase activity utilized His6-moesin (10 µg/ml) as a substrate in the phosphorylation reaction described above. Cells from patients with AML were obtained by leukapheresis. Cells were pelleted at 500 × g, rinsed with PBS, and stored in BSB (10 mM Na2HPO4, pH 6.5, 2 mM EDTA, 1 mM EGTA) at -70 °C. Forty ml of packed cells were thawed, suspended in BSB containing 10 µg/ml each of leupeptin, aprotinin, and pepstatin A, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 10 µM NaF, 1 mM Na3VO4, and homogenized in a Brinkmann Polytron. The homogenate was centrifuged at 20,000 × g for 20 min, and the resulting supernatant was used for sequential ammonium sulfate fractionation. A 35-60% saturated ammonium sulfate precipitate was collected by centrifugation, dissolved in BSB, and then desalted on Sephadex G-50 (50 ml) equilibrated in BSB. The eluate was applied to a 20-ml CM-cellulose column equilibrated in BSB and rinsed with 2 column volumes of buffer. A step gradient from 0.05 to 0.3 M NaCl was used to elute protein kinase activity from the column. Active fractions were pooled and desalted into DEAE buffer (20 mM Tris-HCl, pH 7.5, 0.1% 2-mercaptoethanol, 10 µM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA) using an Amicon ultrafiltration cell. The sample was applied to a Millipore DEAE 8HR column and eluted with a linear gradient from 0 to 0.5 M NaCl in DEAE buffer. Active fractions were pooled and desalted into DEAE buffer and then fractionated on heparin-Sepharose. The heparin-Sepharose column was eluted with a gradient from 0 to 2.0 M NaCl in DEAE buffer containing 0.1 mM EDTA, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 1 µM NaF, and 1 mM Na3VO4. Glycerol was added to each column fraction to obtain a final concentration of 10% before freezing at -70 °C.

Transfection of Jurkat T-lymphoblastic Cells with pEF-PKC-theta His6 and Purification on Ni2+ Affinity Beads-- Jurkat Tag cells are stably transfected with the SV40 large T antigen, which is used to promote expression of genes cloned in the pEF vector (16). pEF-PKC-theta contains the complete coding region of PKC-theta and an in-frame His6 tag at the C terminus. Cells (2 × 107) were electroporated with 20 µg of pEF-PKC-theta or pEF-neo (empty vector control) plasmids in a volume of 400 µl of RPMI 1640 medium using a Bio-Rad Gene Pulser set at 260 V and 960 microfarads. The cells were transferred to a flask containing 10% fetal calf serum in RPMI medium and 700 µg/ml G418 and grown for 48 h. The cells were harvested, rinsed with PBS, and then lysed in 1 ml of binding buffer (1% Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 µg/ml each of leupeptin, aprotinin, pepstatin, and 1 mM phenylmethylsulfonyl fluoride) for 15 min at 4 °C. Lysates were centrifuged at 15,000 × g for 15 min, and the supernatants were used for purification using 0.1 ml of Ni2+ affinity beads. The beads were mixed with supernatants for 60 min at 4 °C and then rinsed twice with 1 ml of binding buffer and then three times with 1 ml of binding buffer containing 50 mM imidazole, pH 6.5. The beads were then rinsed once with TBS to remove detergent, and bound proteins were eluted by incubation of the beads in 0.1 ml of 500 mM imidazole, pH 6.5, in TBS containing 10 µg/ml bovine serum albumin and 50% glycerol for 15 min at 4 °C. Aliquots of the eluates from the Ni2+ affinity beads were subjected to SDS-PAGE and immunoblotting with anti-PKC-theta (V3-specific) and anti-His6 antibodies. Both antibodies detected a single immunoreactive band at 80 kDa in the eluate from the pEF-PKC-theta -transfected cells but not pEF neo-transfected cells.

Immunoblotting-- Proteins were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes in 62 mM Tris, 190 mM glycine containing 20% methanol at 280 mA for 45 min. The membranes were stained with Ponceau S in 1% acetic acid to identify the molecular weight standards and destained in PBST (PBS containing 0.01% Tween 20). The blots were incubated with 5% non-fat dry milk in PBST for 15 min and then with primary antibodies for 60 min. After several rinses in PBST, the blots were incubated with horseradish peroxidase-conjugated anti-mouse or rabbit IgG for 30 min and then rinsed with PBST before detection with ECL reagent (Amersham).

Phospholipid Binding of PKC-theta -His6-- Chloroform solutions of lipid were dried with a stream of N2, and the dried lipid was suspended in water at a concentration of 1 mg/ml with vigorous vortexing. The solution was sonicated in a 20 °C water bath for 15 min to give phospholipid vesicles, and buffer was added to give a stock concentration of 0.5 mg/ml phospholipid, 0.5 M Tris-HCl, pH 7.5, 0.5 M NaCl. Phospholipid vesicles (100 µg/ml final concentration) were mixed with or without His6-moesin (0.5 µg) and/or expressed PKC-theta -His6 in a buffer containing 3 mM Mn2+, 20 µM ATP, and 10 µg/ml leupeptin, 100 mM Tris-HCl, pH 7.5, and 100 mM NaCl in a 0.5-ml microcentrifuge tube. The samples were incubated at 37 °C for 10 min and then for an additional 10 min on ice. The tubes were centrifuged at 12,000 × g for 15 min at 4 °C to obtain supernatant and pellet fractions, which were subjected to immunoblot analysis. Prior to the addition of PKC-theta -His6 and His6-moesin to vesicles, the solutions were centrifuged at 12,000 × g for 10 min to remove aggregated protein.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Properties of the Partially Purified Kinase System-- The partial purification of pp73 from 40 ml of human leukemic cells utilized the same ammonium sulfate precipitation and CM-cellulose chromatography as were used previously for identifying pp47, which is phosphorylated under similar conditions (see "Materials and Methods"). The peak CM-cellulose fractions for pp73 purification were obtained at 0.1-0.15 M NaCl and contained both enzyme and substrate but very little phosphatase. We estimated purification at this step at about 100-fold, based upon a 50% yield estimate, which was inexact due to phosphatases in the starting material.

As shown in Fig. 1, the partially purified system exhibits characteristics similar to our previous observations in whole cell extracts, with lane 3 demonstrating optimal phosphorylation of pp73 with Mn2+ and PG (3). The order of phospholipid preference was PG > PI > PS > no lipid, shown in lanes 3, 2, 5, and 1, respectively. We also wished to determine whether the phosphorylation was due to cyclic AMP-dependent protein kinase (PKA) or to classical PKC. In lane 4, addition of rat brain PKC, under optimal conditions for phosphorylation of pp73, i.e. Mn2+ and PG, resulted in a decrease in pp73 phosphorylation compared with the CM-cellulose fraction alone in lane 3. In lane 7, addition of rat brain PKC in the presence of PS/DAG/Ca2+ resulted in the phosphorylation of a 75-kDa protein, not pp73. In contrast to the lack of phosphorylation of pp73, the talin fragment was heavily phosphorylated in lane 7 compared with lane 6, merely by the addition of rat brain PKC. In lane 9, addition of the catalytic subunit of PKA under optimal PKA conditions gave almost no phosphorylation of pp73, whereas a band of about 55 kDa was heavily phosphorylated. Thus the CM-cellulose fraction exhibited the Mn2+ dependence and PG preference in phosphorylation noted previously, and the phosphorylation was not due to PKA or to classical PKC which is stimulated by PS/DAG/Ca2+.


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 1.   Phosphorylation of a CM-cellulose fraction of leukemic cell proteins under various conditions. The products were resolved by SDS-PAGE, and the resulting autoradiogram is shown. The conditions under which the phosphorylations were conducted are given in the legend above the autoradiogram. PKC refers to purified rat brain PKC, which contains a mixture of isozymes alpha , beta , gamma , epsilon , lambda , zeta , iota , and delta , and PKA refers to the catalytic subunit.

Purification and Identification of pp73-- Since two-dimensional gels showed that there were no significant amounts of other proteins at this pI (~6.5, data not shown), a preparative purification was conducted using adherence of proteins to PG vesicles under assay conditions as above. This was followed by isoelectric focusing in a sucrose gradient (12), and fractions containing pp73 were identified by SDS-PAGE and autoradiography. These fractions were digested with trypsin, and the resulting peptides were separated by HPLC. Three peptide sequences were obtained and were found to be identical to the ERM protein moesin (Table I). The peptide sequences are inconsistent with those of the closely related proteins ezrin (17), radixin (18), merlin/schwannomin (19, 20), or talin (21).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of three tryptic peptides from pp73 are identical to moesin
Purification of pp73 by ion exchange, adherence to PG vesicles, and isoelectric focusing were performed as described under "Materials and Methods." The resulting protein was >90% pure by two-dimensional electrophoresis and was submitted to the W. M. Keck Biotechnology Resource Laboratory for trypsin digestion, separation of the resulting peptides by HPLC, and microsequencing of three selected peptides. The sequences are compared to homologous sequences of human Moesin, Ezrin, Radixin, and Merlin with identical residues indicated by the dots.

Phosphorylation of Bacterially Expressed Moesin-- To confirm the peptide sequencing identification, we tested recombinant His6-moesin for its ability to be phosphorylated by endogenous kinase in the CM-cellulose fraction from leukemic cells. Fig. 2 shows that the phosphorylation of recombinant moesin is PG-stimulable (lane 4 versus lane 3) and that the amount of phosphorylation is roughly comparable to the phosphorylation of endogenous pp73 on a per weight basis (lane 4 versus lane 2). As a control, there is no kinase activity in the purified recombinant moesin fraction alone (lane 5). The cyanogen bromide fragmentation patterns of pp73 and recombinant moesin are identical upon SDS-PAGE (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 2.   Recombinant moesin is phosphorylated by moesin kinase. Recombinant moesin containing a six-histidine tag was purified by nickel chelate affinity chromatography and CM-cellulose chromatography. CM-cellulose fraction proteins from AML cells were phosphorylated without and with recombinant moesin (r-moe), and the recombinant moesin was phosphorylated alone. The products were resolved by SDS-PAGE; proteins were visualized with Coomassie Blue, and an autoradiogram was obtained. The additions for the phosphorylation reactions are give in the legend above the figures. A, autoradiogram. B, Coomassie Blue stain.

In Vitro Phosphorylation of Moesin Is on Threonine 558-- Since ezrin has been reported to be multiply phosphorylated, we determined the extent of our in vitro reaction in two ways. First, the maximum phosphate we were able to incorporate was 0.8 mol of phosphate per mol of moesin, which suggests only one phosphorylation. Second, two-dimensional gel electrophoresis was performed on moesin (22), which showed two spots (Fig. 3, top) labeled 1 and 2. Carbamylation of His6-moesin (23) generated a charge train of spots which established that the distance between 1 and 2 corresponded to 1 charge unit (data not shown). It is probable that spot 2 is the deamidation product of spot 1, since moesin contains an asparagine-glycine sequence, which is most permissive for deamidation at mild pH and temperature (24), and we observed that more of spot 2 was produced by longer storage. Phosphorylation to approximately 20% gave two more spots (Fig. 3, middle) labeled 3 and 4; these spots were radioactive (Fig. 3, bottom). We interpret the data to infer that a single phosphorylation of native moesin, spot 1, produces spot 3 and that a single phosphorylation of deamidated moesin, spot 2, gives spot 4. Moesin phosphorylation did not result in additional spots. A similar pattern of spots using recombinant phospho- and dephospho-moesin was observed upon two-dimensional gel analysis (data not shown).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 3.   Two-dimensional gel analysis of a mixture of His6-moesin and moesin (top) and of His6-moesin and 20% phosphorylated moesin (middle and bottom). One-half microgram of His6-moesin and 1 µg of moesin were used. The isoelectric focusing was done as described (22) using 0.6% Ampholines, pH 6-7, and 0.4% Ampholines, pH 3.5-10; spot 1 corresponds to about pH 6.6, and spot 4 corresponds to about pH 6.45. Only a small section of the gel is shown.

We next determined the site of phosphorylation in moesin. Phosphoamino acid analysis showed that greater than 95% of the label was on threonine. Cyanogen bromide fragmentation of phosphorylated moesin showed one main radioactive fragment by SDS-PAGE (25) of about 3 kDa. About 80% of the radioactivity was in a single peak of approximately 3 kDa. Analysis of this peptide by mass spectrometry showed a peak at 3,517 Da, which is exactly the mass expected of a phosphorylated moesin CNBr fragment (550RLGRDKYKTLRQIRQGNTKQRIDEFESM577). Manual Edman degradation of this peptide coupled to an arylamine membrane (13) revealed significant release of radioactivity at cycle 9, corresponding to threonine 558 (Thr558). Ezrin also contains this sequence, and human placental ezrin (kindly provided by A. Bretscher, Cornell University) was phosphorylated by our preparations of kinase at about the same rate as moesin was phosphorylated (data not shown).

Moesin Kinase Activity Is Not a Classical PKC-- Moesin kinase was purified from phosphatases using DEAE chromatography (see below), and its activity upon moesin and the purified 47-kDa talin fragment were tested under conditions optimal for moesin phosphorylation and optimal for most forms of PKC. In Fig. 4, lanes 1 and 3, negligible levels of phosphorylation of both moesin and talin fragment are seen in the absence of added lipid. In lane 2, enzyme added under conditions optimal for moesin kinase activity shows heavy labeling of both moesin and talin fragment. In lane 4, enzyme added under conditions optimal for most forms of PKC leads to heavy labeling of talin fragment and a negligible increase in labeling of moesin. Addition of a purified rat brain PKC preparation under optimal PKC conditions showed the same heavy phosphorylation of talin fragment and negligible phosphorylation of moesin (data not shown). Thus, conventional activation conditions for PKC do not account for the PG-stimulable moesin kinase activity. However, we could not discount the possibility that phosphorylation of moesin might be due to a novel or unusual activation of a PKC isozyme.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 4.   Moesin kinase does not phosphorylate moesin under classical PKC conditions. Moesin, talin fragment, and partially purified moesin kinase purified free of phosphatase activity were assayed as shown under conditions optimal for moesin kinase and for most PKC isoforms (see "Materials and Methods"). The products were separated by SDS-PAGE, and an autoradiogram of the resulting gel is shown. The upper band corresponds to moesin, and the lower band is the 47-kDa talin fragment.

The Phosphorylation Site of Moesin Is Homologous to a PKC Pseudosubstrate Sequence-- As an aid to identifying potential protein kinases that phosphorylate moesin, we examined the amino acid sequence of the phosphorylation site to determine whether it had sequence similarity with consensus protein kinase recognition sequences in other proteins (26). The phosphorylation site, KYKT*LRQ (where * indicates the phosphorylation site), was found to resemble the pseudosubstrate sequence found in the PKC family of enzymes. The sequence contains the requisite basic residues surrounding the phosphorylation site threonine with the phosphorylated residue, Thr558, at the alanine position in the pseudosubstrate sequences. As shown in Table II, homology is maximal with the novel PKC isozymes theta  and delta  (75%) compared with the conventional isozymes alpha , beta , and gamma  (50%) and the isozymes epsilon , eta , and zeta  (38-50%). Although there is a mismatch between PKC-theta or PKC-delta and moesin of the two residues immediately N-terminal of Thr558, one basic residue within this span is common to all the sequences. This finding suggested that a novel PKC isozyme may be the moesin kinase we detected.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Comparison of the moesin phosphorylation site sequence with the pseudosubstrate sequences of PKC isozymes
Percent homology was calculated based on the number of identical and conserved amino acids indicated in bold by using eight amino acid residues surrounding the phosphorylated threonine in Moesin and alanine in the pseudosubstrate sequences of the PKC isozymes.

Immunological Identification of Moesin Kinase Activity as PKC-theta -- Due to the high degree of sequence similarity of the moesin phosphorylation sequence with PKC-theta and delta , we analyzed the CM-cellulose fraction for the presence of PKC isozymes by immunoblotting. As shown in Fig. 5A, the CM-cellulose fraction contains three PKC isozymes, theta , alpha , and delta . The apparent relative abundance of the theta  and delta  isozymes is consistent with their known expression in hemopoietic cells. We next examined whether antibodies to specific PKC isozymes could immunodeplete moesin kinase activity from the CM fraction. As shown in Fig. 5B, antibodies raised against the V3 region of PKC-theta (7) removed >90% of the activity, whereas antibodies to the other PKC isozymes did not remove or inhibit moesin kinase activity. IgG specific for the C terminus of PKC-theta (Fig. 5B, anti-PKC-theta , C-Term) is less efficient at immunodepletion of kinase but was also correspondingly less efficient at immunoprecipitation of PKC-theta protein as assessed by immunoblotting. In Fig. 5C, analysis of the immunoprecipitate formed with anti-PKC-theta (V3-specific) by immunoblotting with anti-PKC-theta and alpha  indicated that only PKC-theta is in the immunoprecipitate and that PKC-alpha is not. Anti-PKC-theta IgG does not cross-react with PKC-alpha , the next most abundant PKC isozyme in the CM fraction (Fig. 5, compare A and C). However, we were unable to demonstrate activity in the immunoprecipitates, possibly due to the inactivation of the enzyme bound to IgG and protein A/G beads or an inability of the bound enzyme to be optimally activated with phosphatidylglycerol vesicles. Taken together, these data suggest that the moesin kinase activity in the CM-cellulose purified cell extracts is attributable to PKC-theta .


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Immunological identification of moesin kinase activity as PKC-theta . An aliquot of the CM fraction containing moesin kinase activity was subjected to immunoblotting with PKC isozyme-specific monoclonal antibodies (A) as indicated in the figure. The sizes of the full-length PKC-alpha , -delta , and -theta are 82, 78, and 80 kDa, respectively. The additional bands of lower molecular mass detected with alpha - and theta -specific antibodies are degradation products. B, immunodepletion of moesin kinase activity with 1 µg of each isozyme-specific anti-PKC IgG as indicated or with control rabbit IgG or no IgG (-IgG). An aliquot of the CM-cellulose fraction was incubated with IgG fractions from antisera specific for each isozyme, followed by protein A/G agarose to remove IgG and immune complexes. An identical amount of the supernatant fraction from each immunoprecipitation was used to assay moesin kinase activity. The kinase activity was assayed using His6-moesin (arrow). The minus (-) enzyme lane contains no added enzyme. The immunodepletion and moesin kinase assays were carried out as described under "Materials and Methods." C, immunoprecipitation (IP) of moesin kinase activity and detection of PKC-theta in the immunoprecipitate. An aliquot of the CM-cellulose fraction was subjected to immunodepletion with the V3-specific anti-PKC-theta (labeled theta ) or non-immune IgG (N) as described in B, and the immunoprecipitates were analyzed by immunoblotting with the monoclonal anti-PKC-theta and anti-PKC-alpha . The position of PKC-theta at 80 kDa is indicated by the arrow.

Partial Purification of PKC-theta from AML Cells-- We next endeavored to purify the moesin kinase activity from human AML cells using His6-moesin as a substrate in our standard assay (see "Materials and Methods"). Immunoreactivity of individual fractions with anti-PKC-theta , as well as anti-PKC-alpha , was also monitored. A 35-65% ammonium sulfate fraction of the cell lysate was chromatographed over a CM-cellulose column, and aliquots of each fraction were assayed using PG vesicles (Fig. 6A, upper panel), and in addition PS/DAG without Ca2+ to assay for novel PKCs (Fig. 6A, middle panel). PG-stimulable moesin kinase activity elutes from the column at about 0.09-0.18 M NaCl; activity in the presence of PS/DAG/EGTA is about 10-fold lower than with PG. Immunoblot analysis of the CM-cellulose fractions indicates that the fractions displaying moesin kinase activity contain PKC-theta (Fig. 6A, lower panel), as well as PKC-alpha (data not shown). No PKC-theta immunoreactivity was found in side fractions. A pool of the active CM-cellulose fractions eluting at 0.09-0.18 M NaCl was fractionated on a DEAE 8HR column. As shown in Fig. 6B, two pools of moesin kinase activity using PG vesicles are found. A major peak of activity eluting at a lower [NaCl] in fractions 4-6 contain PKC-theta , whereas fractions 8-12, which display lower PG-stimulable moesin kinase activity, contain PKC-alpha . The peak of moesin kinase activity and PKC-theta immunoreactivity is found in fraction 5, which has no detectable PKC-alpha . This chromatographic step effectively separates PKC-theta and PKC-alpha and enriches the moesin kinase activity in fractions containing PKC-theta . Fraction 5 was used for heparin-Sepharose chromatography because it contained maximal moesin kinase activity and PKC-theta . The moesin kinase activity again co-fractionates with intact PKC-theta as detected by immunoblotting (Fig. 6C). Furthermore, the activity obtained cannot be ascribed to the catalytic fragment of PKC-theta in the preparation because no immunoreactive fragment was detected with a PKC-theta antibody directed to the C terminus. The peak of moesin kinase activity and PKC-theta immunoreactivity also coeluted from a Superdex-200 FPLC column at 85 kDa, which is consistent with the molecular mass of PKC-theta (data not shown). Therefore, the purification used here results in the enrichment of moesin kinase activity corresponding to intact PKC-theta and removes the immunoreactive fragment present at the CM-cellulose step (Fig. 5A). However, attempts to purify the moesin kinase activity further resulted in a drastic loss of phosphorylating activity, which precluded direct sequencing of purified kinase. A similar loss of activity with purification has been observed for some PKC isozymes, for example PKC-delta purified from K562 hematopoietic cells (27) and PKC-eta from murine brain (28). All further experiments using PKC-theta from AML cells were done with a kinase preparation containing the full-length enzyme as determined by SDS-PAGE/immunoblotting and Superdex-200 chromatography.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Partial purification of PKC-theta from AML cells. A, CM-cellulose chromatography. The column was eluted with a 0-0.3 M NaCl gradient. Aliquots of the fractions were assayed for moesin kinase activity using His6-moesin as a substrate and PG vesicles (upper panel), for PS/DAG/EGTA-stimulated PKC activity using His6-moesin as a substrate (middle panel), and for PKC-theta immunoreactivity (V3 region-specific). B, Millipore DEAE 8HR column; the fractions from the CM-cellulose column eluting at 0.09-0.14 M NaCl were pooled and chromatographed on a Millipore DEAE 8HR column using a linear 0-0.5 M NaCl gradient and assayed for moesin kinase activity with PG vesicles (arrow, His6-moesin), and for immunoreactivity with antibodies specific for PKC-theta and PKC-alpha (arrows). C, heparin-Sepharose chromatography: DEAE fraction 5 was subjected to heparin-Sepharose chromatography using a 0-0.5 M NaCl gradient. Fractions were assayed for moesin kinase activity and for PKC-theta immunoreactivity. The positions of phosphorylated His6-moesin and immunoreactive PKC-theta and PKC-alpha are indicated by arrows.

Preferential Activation of Moesin Kinase (PKC-theta ) by PG Vesicles-- We next examined the activation of moesin kinase by PG and PS in combination with DAG. Previous studies using the [A25S]PKC substrate peptide, which corresponds to the pseudosubstrate sequence of PKC-alpha with an alanine to serine substitution, showed that PS at optimal concentrations gave near maximal activation of PKC-theta in the absence of either phorbol 12-myristate 13-acetate or DAG (Ref. 29, Fig. 5). We examined the activation of moesin kinase with PG and PS vesicles with added DAG constituting 10% (30) of the total lipid concentration of either 20 and 200 µg/ml. As shown in Fig. 7, addition of DAG to PG vesicles did not lead to increased moesin phosphorylation. By using PS and PS/DAG vesicles, less moesin phosphorylation was obtained compared with PG vesicles. Addition of 10% DAG to PS vesicles led to a minimal increase in moesin phosphorylation (Fig. 7, compare 100% PS and 90% PS + 10% DAG) and is more evident using 20 µg/ml total lipid. In addition, we investigated activation of PKC-theta using PC vesicles containing 20% acidic lipids (PG, PS, or PI), a typical concentration of the inner leaflet of the plasma membrane (31). PC vesicles alone did not activate PKC-theta . PG, in mixed vesicles with PC, maximally activated PKC-theta , and DAG again had no effect (data not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   PG preference of partially purified PKC-theta . An aliquot of fraction 8 from the heparin-Sepharose purified kinase was assayed with His6-moesin as described under "Materials and Methods," except the lipid composition was changed as indicated. A reaction performed without lipid is indicated by the symbol above the figure.

Moesin Kinase (PKC-theta ) Activity toward Different Substrates-- We next tested whether the moesin kinase activity has particular substrate and cofactor requirements. By using moesin, MBP, and histone H1, the kinase activity toward each was tested in the presence of PG, PI, or PS/DAG. As shown in Fig. 8, maximal kinase activity was obtained using PG and His6-moesin, whereas the kinase activity toward MBP was lipid-independent, and histone H1 phosphorylation was minimal. These results are consistent with previous findings of PKC-theta using an MBP-derived peptide and histone H1 (29).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 8.   Substrate and lipid dependence of moesin kinase activity. Aliquots of fraction 8 from the heparin-Sepharose column were assayed using His6-moesin (H6M), myelin basic protein (MBP), and histone H1 in the presence of PG, PI, and PS/DAG phospholipid vesicles. The lanes indicated by the lines are reactions in buffer alone without added lipid. H6M, MBP, and Histone H1 are 73, 22, and 34 kDa, respectively.

Recombinant His6-PKC-theta Phosphorylates Moesin-- To verify that PKC-theta phosphorylates moesin, we transfected eukaryotic cells with a plasmid bearing PKC-theta with a His6 tag at its C terminus (16, 29). Jurkat (T-lymphoblastic leukemia) cells were transfected with the His6-PKC-theta plasmid and with the neo vector alone. Cell lysates from each transfection were purified by Ni2+ affinity chromatography, and aliquots of the eluates were analyzed by SDS-PAGE. Immunoblotting with anti-His6 probe antibody indicated that cells transfected with pEFPKC-theta , but not pEFneo, contained a single immunoreactive band at 80 kDa (data not shown). Furthermore, immunoblotting with anti-PKC-theta revealed that only the pEF-PKC-theta -transfected cells express recombinant enzyme that is purified on the Ni2+ affinity beads and that no endogenous Jurkat cell PKC-theta is purified on the beads (Fig. 9A). We next used the purified His6-PKC-theta in the moesin kinase assay to determine whether the recombinant enzyme could phosphorylate moesin. As shown in Fig. 9B, recombinant His6-PKC-theta phosphorylated moesin in the presence of PG or PI vesicles, lanes 2 and 4, whereas no phosphorylation was detected using Ni2+ affinity purified extracts from neo-transfected cells, lanes 1 and 3.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 9.   Expressed PKC-theta -His6 phosphorylates moesin. Jurkat Tag cells were electroporated with pEF plasmids containing PKC-theta -His6 and empty vector (pEF neo), and cell lysates were purified on Ni2+ affinity beads. A, The eluates and unbound (UNBD) fractions were subjected to immunoblot analysis with anti-PKC-theta (V3-specific). B, the Ni2+ column eluates from neo and PKC-theta -His6-transfected cells were assayed using PG and PI phospholipid vesicles and His6-moesin.

Moesin and PKC-theta Bind to PG Vesicles-- Next, we investigated the association of PKC-theta with PG vesicles and whether moesin is required for the binding. PG vesicles were incubated with Ni2+ affinity purified PKC-theta -His6 and His6-moesin, and vesicles were pelleted by centrifugation. The vesicle-bound and unbound PKC-theta was identified by immunoblotting. As shown in Fig. 10, PKC-theta was found in the pellet fractions of reactions containing PG vesicles, and binding was independent of His6-moesin. Furthermore, about 50% of the His6-moesin was pelleted in association with PG vesicles.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 10.   Association of moesin and PKC-theta with PG vesicles. Aliquots of PKC-theta -His6 were incubated with PG vesicles (+) or buffer (-), as well as in the presence (+) or absence (-) of His6-moesin (H6M) as described under "Materials and Methods." The vesicle pellet fractions (P) and supernatants (S) were analyzed by SDS-PAGE and immunoblotting with PKC-theta monoclonal antibody. The position of His6-moesin on the Ponceau S-stained blot is indicated by the arrow. The intensely stained band corresponds to bovine serum albumin present in the PKC-theta -His6 preparation.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this report we present reaction conditions under which PKC-theta threonine phosphorylates moesin at its previously identified in vivo site within its actin-binding domain (1). PKC-theta is a recently discovered novel PKC isozyme, which has not previously been shown to phosphorylate moesin or to require the unusual conditions defined here nor has it been linked to any other substrate of likely physiological significance. Although phosphorylation of ERM proteins has been previously described, the work we present is the first evidence linking proteins of this class to a specific kinase and suggests a novel and specific signaling pathway regulating membrane-cytoskeleton linkages.

The reaction conditions described here result in greatly increased phosphorylation of the prominent 73-kDa protein substrate we originally described in hemopoietic cells (3-5), which we here identify as moesin on the basis of protein purification followed by microsequencing and confirm by phosphorylation of recombinant moesin with partially purified kinase. Several further observations corroborate this identification. First, both pp73 and PKC-theta bind to PG vesicles, and moesin is known to bind to the plasma membrane (32, 33). Second, in Fig. 2 we observed four spots of pp73 by two-dimensional gel analysis with pI ranging from 6.6 to 6.45, which is similar to the four spots of moesin reported in a comprehensive protein data base (34). Our results indicate that the latter distribution results from deamidation and mono-phosphorylation.

By using recombinant moesin as a substrate for in vitro kinase assays, we have partially purified and identified PKC-theta as a protein kinase that phosphorylates moesin at Thr558 in the actin-binding domain, and we further conclude that it corresponds to the protein kinase previously described (3). This identification is based upon immunodepletion experiments and the demonstration of moesin phosphorylation by recombinant PKC-theta . The phosphorylation site of moesin, KYKTLRQ, containing Thr558, is phosphorylated by a partially purified PKC-theta preparation and is highly homologous with the pseudosubstrate sequence of PKC-theta . The lipid dependence of PKC-theta phosphorylation of moesin displays a preference for PG over PS vesicles, with minimal contribution to activation by DAG. Furthermore, both moesin and PKC-theta associate with PG phospholipid vesicles, and PKC-theta displays a strict substrate preference for moesin, rather than MBP or histone H1. PKC-theta is thus the major moesin kinase directly identifiable in the cell extracts we studied. The single phosphorylation site identified corresponds exactly with that which is now well established to occur in cells (1, 33). We are currently extending this work to test further our putative PKC-theta /moesin link in cellular systems and to analyze its control and effects. We cannot, however, rule out the participation of other moesin kinases in other cell types or tissues or under other activating conditions. This is especially a consideration since ERM proteins are ubiquitous, whereas PKC-theta is not. PKC-alpha can phosphorylate moesin, albeit at an apparently lower rate, which may be adequate to elicit a physiologic response.

ERM proteins are involved in a wide variety of cellular functions, including cell-cell adhesion, cell-substrate adhesion, microvillar structure, and cytokinesis. Moesin was first isolated by its ability to bind heparin (36); subsequent cDNA cloning and sequence analysis showed it to be a 68-kDa protein related to a family of proteins involved in linking the membrane of a cell to its cytoskeleton (32). The ERM proteins identified to date have a common domain structure based upon amino acid sequence homology to the erythrocyte band 4.1 protein. They are comprised of an N-terminal domain which is involved in membrane binding, an alpha -helical central domain, and a C-terminal actin-binding domain (37). In vitro work has shown that native ERM proteins bind to beads displaying the cytoplasmic tail of the transmembrane protein CD44 at physiological ionic strength in the presence of phosphatidylinositol-4,5-diphosphate (38). Ezrin has been shown to bind filamentous beta -actin, not alpha -actin, at physiological ionic strength (39), whereas such an interaction between moesin and F-actin has not yet been demonstrated. The ezrin/beta -actin interaction correlates with the fact that beta -actin and ezrin are colocalized to diverse cellular extensions, whereas alpha -actins are largely restricted to sarcomeres and stress fibers (40, 41).

Does moesin phosphorylation affect actin binding? Moesin was originally immunolocalized to structurally and functionally diverse cellular extensions, and it was speculated that these "rapidly assembled cell surface structures may be akin to environmental sensors in a very general sense" and that phosphorylation of moesin might be related to these morphological changes (33). The Thr558 site in moesin was phosphorylated in platelets upon thrombin stimulation, which drastically alters platelet shape. Using a phosphorylation state-specific antibody to KYKpT558LR, only a fraction of total moesin molecules found in filopodia and retraction fibers are phosphorylated in RAW macrophages (35). In the presence of the phosphatase inhibitor calyculin A, phosphorylated moesin is increased to nearly 100% and is redistributed from filopodia and retraction fibers into an F-actin containing ring-like structure in the cytoplasm. Thus, this phosphorylation step accompanies actin-based morphological changes (1). We are currently investigating possible interactions of moesin and phosphorylated moesin with various actin isoforms.

ERM proteins have now been shown to interact with several molecules and signaling pathways in addition to those described here. Tsukita and co-workers (38) found that the affinity of the moesin and ezrin interaction with the cytoplasmic tail of CD44 was markedly enhanced by phosphoinositides. In A431 cells, the redistribution of ezrin into membrane ruffles after epidermal growth factor stimulation is concomitant with both serine and tyrosine phosphorylation (42). Studies using gastric mucosal cells indicate that ezrin associates with the regulatory (RII) subunit of PKA, suggesting that ezrin functions as an protein kinase A anchoring protein (AKAP) (43). The RII-binding site in ezrin, corresponding to residues 417-432, is highly conserved in moesin and corresponds to the RII-binding site in the C terminus of AKAP79 (44). Additionally, AKAP79 contains a binding sequence for PKC in the N terminus, and a peptide corresponding to this sequence inhibits PKC activity. A similar PKC-binding site has not been identified in either ezrin or moesin, but several sites in ezrin/moesin have significant homology with this sequence in AKAP79. We demonstrate that moesin is not phosphorylated by the catalytic subunit of PKA (Fig. 1) but is phosphorylated at the KYKTYLRQ site in the actin-binding domain by PKC-theta . ERM proteins may participate in a dynamic, macromolecular signaling complex, analogous to the model proposed by Faux and Scott (45) in which AKAP79 anchors PKC, PKA, and phosphatase 2B at neuronal synapses. ERM proteins may similarly function as anchoring proteins linking the actin cytoskeleton with phospholipid, phosphatidylinositol-4,5-diphosphate, CD44, PKA, and PKC. Our data demonstrating that moesin and PKC-theta bind to phospholipid vesicles and that the phosphorylation site sequence in moesin is homologous to the pseudosubstrate sequence of PKC-theta support this hypothesis. Furthermore, preliminary immunofluorescence studies show significant colocalization of PKC-theta and moesin in punctate structures within protrusions at the cell periphery in RAW macrophages and HL-60 cells (data not shown). This pattern appears similar to that recently described for PKC-theta in resting T-cells (46). Thus, PKC-theta may regulate the interaction of ERM proteins with the actin cytoskeleton and may also interact with other components of such a complex.

The PKC family of serine/threonine kinases consists of multiple isozymes that are grouped into three categories based on their cofactor and lipid dependence for activation. The conventional PKCs (alpha , beta I, beta II, and gamma ) are activated by Ca2+, phospholipid, and DAG; novel PKCs (delta , theta , epsilon , and eta ) are insensitive to Ca2+, and the atypical PKCs (zeta  and iota /lambda ) are insensitive to both Ca2+ and DAG (47). Although some isozymes have widespread tissue and cell type distribution (alpha , delta , and zeta ), other isozymes such as PKC-gamma , -eta , and -theta are more restricted. PKC-theta is the main novel isozyme expressed in skeletal muscle, testes, platelets, and their megakaryoblastic precursor cells, T-lymphocytes, and neoplastic hemopoietic cells (7, 48, 49). We have found moesin phosphorylation activity in HL-60 cells, spleen cells, and AML cells, which is consistent with the known distribution of PKC-theta (29) and in contrast to the tissue distribution of the µ (50) and the lambda /iota isoforms, which are not found in spleen (51, 52). We have previously described modulation of this activity under various conditions affecting cellular proliferation and differentiation (4, 5). It will be of interest to determine if PKC-theta immunoreactivity is modulated in parallel as expected. If so, this previous work could be the basis for physiologic models of PKC-theta activation and function.

The unusual lipid activation pattern we have observed in vitro in the presence of Mn2+ (PG > PI > PS/DAG) is reminiscent of the unusual lipid activation conditions described for other novel PKCs. Our data demonstrating a minimal contribution of DAG to the PS activation of PKC-theta phosphorylation of moesin is consistent with the findings of Baier et al. (29), who showed a similar minimal effect of phorbol 12-myristate 13-acetate to the PS activation of PKC-theta . A comparable pattern has been observed with PKC-delta phosphorylation of the gamma  chain of the IgE receptor, where the rate of threonine phosphorylation was increased 2.5-fold using PI compared with PS, whereas the effect of PG was not tested (53). PKC-epsilon displays PG-stimulable activity toward a PKC-epsilon synthetic peptide resembling the PKC-epsilon pseudosubstrate site, with a serine residue at the alanine position (54). PKC-epsilon was also found to phosphorylate histones poorly, similar to the present findings with PKC-theta .

The activation of classical and novel PKCs by PS and DAG is thought to reflect an allosteric enzymic effect: DAG generation causes increased PKC membrane affinity and accompanies release of the pseudosubstrate sequence from the active site. However, we suspect the mechanism of PKC-theta activation and moesin phosphorylation to be more complex. Our findings indicate first that both moesin and PKC-theta bind to PG vesicles independently of one another; the phospholipid activation observed may be based upon closely co-concentrating the two components on a suitable surface. Phospholipid binding could also have a role in exposing the moesin phosphorylation site which is otherwise masked by N- and C-terminal domain interactions (58). Moesin phosphorylation is activated by acidic phospholipids (PG, PS, and PI) but not neutral lipids, such as PC or DAG. A similar pattern of binding to acidic phospholipids with subsequent phosphorylation has been described for the PKC substrates neuromodulin and the myristoylated alanine-rich protein kinase C substrate protein (55, 56). Although vesicles containing 20-100% PG support apparently maximal phosphorylation in vitro, further research is necessary to determine what in vivo conditions give rise to basal, stimulated, and possibly inhibited rates. It is likely that membrane binding of moesin and other ERM proteins within cells is under more complex control involving other molecules, such as CD44 and phosphatidylinositol-4,5-diphosphate (36). Other phosphoinositides such as phosphatidylinositol-3,4-P2 and phosphatidylinositol-3,4,5-P3, which are known to activate PKC-delta , -epsilon , and -eta , may also activate PKC-theta and moesin phosphorylation (57). It is equally probable that other natural activators of PKC-theta phosphorylation of moesin and other ERM proteins remain to be elucidated.

The in vivo function of PKC-theta has mainly been studied in cells of the hemopoietic system. The chromosomal location of the human PKC-theta gene was mapped to the short arm of chromosome 10 (10p15), a region that is frequently deleted or subject to translocations in T-cell leukemia, lymphoma, and T-cell immunodeficiency (59). In T-lymphocytes, PKC-theta in conjunction with 14-3-3 may be a constituent of the signaling cascade leading to T-cell activation by activating the AP-1 transcriptional complex (60). Recent evidence clearly shows that antigen stimulation results in the translocation of PKC-theta , along with talin, to the site of contact between T-cells and antigen-presenting cells, whereas in unstimulated cells PKC-theta is found in a punctate distribution (46). The HIV protein Nef, whose association with PKC-theta results in a loss of enzyme, is known to down-regulate CD4 in infected T-cells and blocks interleukin-2 production in Jurkat cells, possibly by inhibiting NFkappa B and AP-1 activation (61). The identification of moesin, ezrin, actin and cofilin inside HIV-1 virions provides evidence for a role of the cytoskeleton in virus budding from microvillar-like pseudopods of infected T-cells (62). Taken together, these findings raise the intriguing possibility that the pathway described here may play a role in virus production from infected T-cells as well as normal T-cell functions.

In summary, this laboratory first characterized the surprisingly specific phosphorylation of two proteins in crude extracts under somewhat unusual conditions: in the presence of Mn+2, the addition of PG or PI vesicles resulted in 10-fold stimulation of phosphorylation (3). We previously identified one of these substrates as the 47-kDa calpain fragment of talin (6), and we here identify the second substrate as moesin. These two proteins are structurally related and are proteins linking the plasma membrane to the actin cytoskeleton. We provide further evidence that the moesin kinase activity corresponds to PKC-theta , using both purified kinase from human leukemic cells and recombinant PKC-theta . The assay requirement for vesicles correlates with their cellular localization on the cytoplasmic surface of the plasma membrane. The in vitro phosphorylation site of moesin Thr558 corresponds to that occurring in activated platelet membranes and in macrophages (1, 35). We are currently investigating such interactions of moesin and PKC-theta within cells to address the physiologic significance of this system.

    ACKNOWLEDGEMENTS

We thank Heinz Furthmayr (Stanford University, Palo Alto, CA) for providing the human moesin cDNA clone and Anthony Bretscher (Cornell University, Ithaca, NY) for providing human placental ezrin. Oligonucleotides used in this study were synthesized by the Protein Chemistry Core Facility at the University of New Mexico School of Medicine. We thank Ken Williams and Kathy Stone at the W. M. Keck Biotechnology Resource Laboratory at Yale University (New Haven, CT) for the amino acid sequencing and mass spectroscopic analyses.

    FOOTNOTES

* This work was supported by Grant CB-158 from the American Cancer Society (to L. E.) and National Institutes of Health Grants CA42520 (to L. E.) and CA35299 (to A. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: University of New Mexico Cancer Center, 900 Camino de Salud NE, Albuquerque, NM 87131. Tel.: 505-272-5837; Fax: 505-272-2841; E-mail: lelias{at}cobra.unm.edu.

1 The abbreviations used are: ERM, ezrin-radixin-moesin; PI, phosphatidylinositol; PS, phosphatidylserine; PG, phosphatidylglycerol; PC, phosphatidylcholine; AML, acute myelogenous leukemia; CM, carboxymethyl; MBP, myelin basic protein; PKA, cyclic AMP-dependent protein kinase; PKC, protein kinase C; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)- propane-1,3-diol; HPLC, high pressure liquid chromatography; DAG, diacylglycerol; AKAP, protein kinase A anchoring protein; HIV, human immunodeficiency virus.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Nakamura, F., Amieva, M. R., and Furthmayr, H. (1995) J. Biol. Chem. 270, 31377-31385[Abstract/Free Full Text]
  2. Pestonjamasp, K., Amieva, M. R., Strassel, C. P., Nauseef, W. M., Furthmayr, H., Luna, E. J. (1995) Mol. Biol. Cell 6, 247-259[Abstract]
  3. Elias, L., and Davis, A. (1985) J. Biol. Chem. 260, 7023-7028[Abstract/Free Full Text]
  4. Klemm, D. J., and Elias, L. (1987) J. Biol. Chem. 262, 7580-7585[Abstract/Free Full Text]
  5. Klemm, D. J., and Elias, L. (1988) Exp. Hematol. 16, 855-860[Medline] [Order article via Infotrieve]
  6. Simons, P. C., and Elias, L. (1993) Blood 82, 3343-3349[Abstract]
  7. Baier, G., Telford, D., Giampa, L., Coggeshall, K. M., Baier-Bitterlich, G., Isakov, N., Altman, A. (1993) J. Biol. Chem. 268, 4997-5004[Abstract/Free Full Text]
  8. Peterson, G. L. (1977) Anal. Biochem. 83, 346-356[Medline] [Order article via Infotrieve]
  9. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  10. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  11. Bruns, K. A., and Elias, L. (1988) Blood 72, 234[Abstract] (Abstr. 81a)
  12. Korant, B. D., and Lonberg-Holm, K. (1974) Anal. Biochem. 59, 75-82[Medline] [Order article via Infotrieve]
  13. Sullivan, S., and Wong, T. W. (1991) Anal. Biochem. 197, 65-68[Medline] [Order article via Infotrieve]
  14. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., pp. 5.28-5.32, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  15. Studier, F. W., Rosenberg, A. H., Dunn, J. J., Dubendorff, J. W. (1990) Methods Enzymol. 185, 60-89[Medline] [Order article via Infotrieve]
  16. Meller, N., Liu, Y. C., Collins, T. L., Bonnefoy-Berard, N., Baier, G., Isakov, N., Altman, A. (1996) Mol. Cell. Biol. 16, 5782-5791[Abstract]
  17. Gould, K. L., Bretscher, A., Esch, F. S., Hunter, T. (1989) EMBO J. 8, 4133-4142[Abstract]
  18. Wilgenbus, K. K., Milatovich, A., Francke, U., and Furthmayr, H. (1993) Genomics 16, 199-206[CrossRef][Medline] [Order article via Infotrieve]
  19. Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Parry, D. M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M., Munroe, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. E., Seizinger, B. R., Short, M. P., Buckler, A. J., Gusella, J. F. (1993) Cell 72, 791-800[Medline] [Order article via Infotrieve]
  20. Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., Pulst, S. M., Lenoir, G., Bijlsma, E., Fashold, R., Dumanski, J., de Jong, P., Parry, D., Eldridge, R., Auriast, A., Delattre, O., Thomas, G. (1993) Nature 363, 515-521[CrossRef][Medline] [Order article via Infotrieve]
  21. Rees, D. J. G., Ades, S. E., Singer, S. J., Hynes, R. O. (1990) Nature 347, 685-689[CrossRef][Medline] [Order article via Infotrieve]
  22. O'Farrell, P. H. (1975) J. Biol. Chem. 250, 4007-4021[Abstract]
  23. Cooper, J. A. (1991) Methods Enzymol. 201, 251-261[Medline] [Order article via Infotrieve]
  24. Paranandi, M. V., Guzzetta, A. W., Hancock, W. S., Aswad, D. W. (1994) J. Biol. Chem. 269, 243-253[Abstract/Free Full Text]
  25. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379[Medline] [Order article via Infotrieve]
  26. Pinna, L. A., and Ruzzene, M. (1996) Biochim. Biophys. Acta 1314, 191-225[Medline] [Order article via Infotrieve]
  27. Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., Weichselbaum, R., Kufe, D. (1995) EMBO J. 14, 6148-6156[Abstract]
  28. Zang, R., Muller, H. J., Kielbassa, K., Marks, F., and Gschwendt, M. (1994) Biochem. J. 304, 641-647[Medline] [Order article via Infotrieve]
  29. Baier, G., Baier-Bitterlich, G., Meller, N., Coggeshall, K. M., Giampa, L., Telford, D., Isakov, N., Altman, A. (1994) Eur. J. Biochem. 225, 195-203[Abstract]
  30. Ogita, K., Ono, Y., Kikkawa, U., and Nishizuka, Y. (1991) Methods Enzymol. 200, 228-234[Medline] [Order article via Infotrieve]
  31. Op den Kamp, J. A. F. (1979) Annu. Rev. Biochem. 48, 47-71[CrossRef][Medline] [Order article via Infotrieve]
  32. Lankes, W. T., and Furthmayr, H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8297-8301[Abstract]
  33. Furthmayr, H., Lankes, W., and Amieva, M. (1992) Kidney Int. 41, 665-670[Medline] [Order article via Infotrieve]
  34. Celis, J. E., Rasmussen, H. H., Madsen, P., Leffers, H., Honore, B., Dejgaard, K., Gesser, B., Olsen, E., Gromov, P., Hoffmann, H. J., Nielsen, M., Celis, A., Basse, B., Lauridsen, J. B., Ratz, G. P., Nielsen, H., Andersen, A. H., Walbum, E., Kjaergaard, I., Puype, M., Van Damme, J., Vandekerckhove, J. (1992) Electrophoresis 13, 893-959[Medline] [Order article via Infotrieve]
  35. Nakamura, F., Amieva, M. R., Hirota, C., Mizuno, Y., and Furthmayr, H. (1996) Biochem. Biophys. Res. Commun. 226, 650-656[CrossRef][Medline] [Order article via Infotrieve]
  36. Lankes, W., Griesmacher, A., Grunwald, J., Schwartz-Albiez, R., and Keller, R. (1988) Biochem. J. 251, 831-842[Medline] [Order article via Infotrieve]
  37. Tsukita, S., Yonemura, S., and Tsukita, S. (1997) Curr. Opin. Cell Biol. 9, 70-75[CrossRef][Medline] [Order article via Infotrieve]
  38. Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y., Tsukita, S., and Tsukita, S. (1996) J. Cell Biol. 135, 37-51[Abstract]
  39. Yao, X., Cheng, L., and Forte, J. G. (1996) J. Biol. Chem. 271, 7224-7229[Abstract/Free Full Text]
  40. Shuster, C. B., and Herman, I. M. (1995) J. Cell Biol. 128, 837-848[Abstract]
  41. Turunen, O., Wahlstrom, T., and Vaheri, A. (1994) J. Cell Biol. 126, 1445-1453[Abstract]
  42. Bretscher, A. (1989) J. Cell Biol. 108, 921-930[Abstract]
  43. Dransfield, D. T., Bradford, A. J., Smith, J., Martin, M., Roy, C., Mangeat, P. H., Goldenring, J. R. (1997) EMBO J. 16, 35-43[Abstract/Free Full Text]
  44. Klauck, T. M., Faux, M. C., Labudda, K., Langeberg, L. K., Jaken, S., Scott, J. D. (1996) Science 271, 1589-1592[Abstract]
  45. Faux, M. C., and Scott, J. D. (1996) Trends Biochem. Sci. 21, 312-315[CrossRef][Medline] [Order article via Infotrieve]
  46. Monks, C. R. F., Kupfer, H., Ta, I., jr, Barlow, A., and Kupfer, A. (1997) Nature 385, 83-86[CrossRef][Medline] [Order article via Infotrieve]
  47. Dekker, L. V., and Parker, P. J. (1994) Trends Biochem. Sci. 19, 73-76[CrossRef][Medline] [Order article via Infotrieve]
  48. Chang, J. D., Xu, Y., Raychowdhury, M. K., Ware, J. A. (1993) J. Biol. Chem. 268, 14208-14214[Abstract/Free Full Text]
  49. Mishak, H., Goodnight, J., Henderson, D. W., Osada, S., Ohno, S., Mushinski, J. F. (1993) FEBS Lett. 326, 51-55[CrossRef][Medline] [Order article via Infotrieve]
  50. Johannes, F. J., Prestle, J., Eis, S., Oberhagemann, P., and Pfizenmaier, K. (1994) J. Biol. Chem. 269, 6140-6148[Abstract/Free Full Text]
  51. Akimoto, K., Mizuno, K., Osada, S., Hirai, S., Tanuma, S., Suzzuki, K., and Ohno, S. (1994) J. Biol. Chem. 269, 12677-12683[Abstract/Free Full Text]
  52. Selbie, L. A., Schmitz-Peiffer, C., Sheng, Y., and Biden, T. J. (1993) J. Biol. Chem. 268, 24296-24302[Abstract/Free Full Text]
  53. Germano, P., Gomez, J., Kazanietz, M. G., Blumberg, P. M., Rivera, J. (1994) J. Biol. Chem. 269, 23102-23107[Abstract/Free Full Text]
  54. Schaap, D., and Parker, P. J. (1990) J. Biol. Chem. 265, 7301-7307[Abstract/Free Full Text]
  55. Seki, K., Sheu, F. S., and Huang, K. P. (1996) Arch. Biochem. Biophys. 326, 193-201[CrossRef][Medline] [Order article via Infotrieve]
  56. Kim, J., Blackshear, P. J., Johnson, J. D., McLaughlin, S. (1994) Biophys. J. 67, 227-237[Abstract]
  57. Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367[Abstract/Free Full Text]
  58. Gary, R., and Bretscher, A. (1995) Mol. Biol. Cell 6, 1061-1075[Abstract]
  59. Erdel, M., Baier-Bitterlich, G., Duba, C., Isakov, N., Altman, A., Utermann, G., and Baier, G. (1995) Genomics 25, 595-597[Medline] [Order article via Infotrieve]
  60. Baier-Bitterlich, G., Uberall, F., Bauer, B., Fresser, F., Wachter, H., Grunicke, H., Utermann, G., Altman, A., and Baier, G. (1996) Mol. Cell. Biol. 16, 1842-1850[Abstract]
  61. Smith, B. L., Krushelnycky, B. W., Mochly-Rosen, D., and Berg, P. (1996) J. Biol. Chem. 271, 16753-16757[Abstract/Free Full Text]
  62. Ott, D. E., Coren, L. V., Kane, B. P., Busch, L. K., Johnson, D. G., Sowder, R. C., Chertova, E. N., Arthur, L., Henderson, L. (1996) J. Virol. 70, 7734-7743[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.